Smith & Nephew acquired BST-CarGel, a first-line cartilage repair product.
Here are five things to know:
1. The product is used along with microfracture and other bone marrow stimulation techniques to treat many sizes of focal cartilage tears.
2. A Smith & Nephew affiliate will acquire ownership of all product and intellectual property assets related to BST-CarGel from Piramal Healthcare Limited.
3. Following a microfracture procedure, surgeons implant the BST-CarGel, a biopolymer-based solution, into the patient's joint.
4. The device acts as a scaffold following implantation and adheres to the cartilage surface to stabilize the blood clot while new cartilage is regenerated.
5. The terms of the transaction were not disclosed.
More articles on devices:
K2M 2015 preliminary revenue up 16%: 5 key notes
SeaSpine preliminary Q4 revenue flat at $35M: 5 key notes
NeuroMetrix estimates its 2015 Q4 revenue at $2.7M — 5 observations